Bayer and Ginkgo Bioworks join forces for sustainable agriculture, forming new company with USD 100 million Series A
The novel company will focus on transformational beneficial microbes for plants to provide growers with next generation solutions to their biggest challenges / Initial activities will focus on nitrogen fixation, minimizing agriculture’s environmental impact / The work combines the synthetic biology leadership of Ginkgo Bioworks with Bayer’s deep knowledge and experience in agriculture and microbial products (Source: Bayer Company News)
Source: Bayer Company News - September 14, 2017 Category: Pharmaceuticals Source Type: news
Bayer places 9.4 percent stake in Covestro
(Source: Bayer Company News)
Source: Bayer Company News - September 13, 2017 Category: Pharmaceuticals Source Type: news
Bayer further reduces holding in Covestro
Accelerated bookbuilding process started (Source: Bayer Company News)
Source: Bayer Company News - September 12, 2017 Category: Pharmaceuticals Source Type: news
Wolfgang Nickl to be new Chief Financial Officer at Bayer AG
(Source: Bayer Company News)
Source: Bayer Company News - September 12, 2017 Category: Pharmaceuticals Source Type: news
Bayer again listed in the Dow Jones Sustainability World Index
Bayer Board member Dr. Klusik:“Sustainability is a core element of our strategy” / Bayer listed continuously in the DJSI World since its inception in 1999 / Index offers investors a guide for making sustainable investments (Source: Bayer Company News)
Source: Bayer Company News - September 7, 2017 Category: Pharmaceuticals Source Type: news
Bayer submits marketing authorization application for BAY94-9027 for the treatment of Hemophilia A in the EU (for specialized target groups only)
Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals (Source: Bayer Company News)
Source: Bayer Company News - September 7, 2017 Category: Pharmaceuticals Source Type: news
Bayer submits Biologics License Application in the U.S. for BAY94-9027 – a long-acting factor VIII for the treatment of Hemophilia A (for specialized target groups only)
Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals (Source: Bayer Company News)
Source: Bayer Company News - August 31, 2017 Category: Pharmaceuticals Source Type: news
Bayer ’s Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24% (for specialized target groups only)
Importantly, rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily showed an unprecedented 42% relative risk reduction in stroke and 22% in cardiovascular death compared with aspirin 100 mg once daily alone / Bleeding rates were low, and while major bleeding was increased, notably there was no significant increase in intracranial or fatal bleeding / This combination regimen demonstrated a substantial improvement in net clinical benefit of 20% (Source: Bayer Company News)
Source: Bayer Company News - August 27, 2017 Category: Pharmaceuticals Source Type: news
Bayer will continue to work constructively
with the European Commission
(Source: Bayer Company News)
Source: Bayer Company News - August 22, 2017 Category: Pharmaceuticals Source Type: news
Bayer Receives EU Approval for Stivarga ® (Regorafenib) for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Approval marks first treatment advance in nearly a decade and is based on data from the Phase III RESORCE study, in which Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) / Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the United States fo r patients with HCC (Source: Bayer Company News)
Source: Bayer Company News - August 7, 2017 Category: Pharmaceuticals Source Type: news
